Abstract: Compounds which are useful as inhibitors of cholesterol biosynthesis and thus as hypocholesterolemic agents are provided which have the structure ##STR1## Z is --(CH.sub.2).sub.n -- or --(CH.sub.2).sub.p --CH.dbd.CH--(CH.sub.2).sub.m --, wherein n is 1 to 5; p is 0, 1 or 2; m is 0, 1 or 2;R, R.sup.1 and R.sup.1a are the same or different and are H, lower alkyl or a metal ion; andR.sup.2 and R.sup.3 may be the same or different and are H or halogen.New intermediates used in preparing the above compounds and method for preparing same, pharmaceutical compositions containing such compounds and a method for using such compounds to inhibit cholesterol biosynthesis are also provided.

Abstract: The disclosure of the present invention is directed to an inositol triphosphate compound, useful as a pharmaceutical agent, having the structural formula ##STR1## where (a) three of R.sub.1, R.sub.3, R.sub.5, R.sub.7, R.sub.10 and R.sub.11 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.6, R.sub.8, R.sub.9 and R.sub.12 are hydrogen;(b) three of R.sub.1, R.sub.3, R.sub.6, R.sub.7, R.sub.9 and R.sub.12 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.5, R.sub.8, R.sub.10 and R.sub.11 are hydrogen;(c) three of R.sub.1, R.sub.3, R.sub.5, R.sub.8, R.sub.10 and R.sub.12 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.6, R.sub.7, R.sub.9 and R.sub.11 are hydrogen;(d) three or R.sub.1, R.sub.4, R.sub.5, R.sub.8, R.sub.9 and R.sub.12 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.3, R.sub.6, R.sub.7, R.sub.10 and R.sub.11 are hydrogen;(e) three of R.sub.1, R.sub.3, R.sub.6, R.sub.8, R.sub.9 and R.sub.

Abstract: Amphoteric and zwitter-ionic phosphate surfactants corresponding to the following formula ##STR1## (a) in which R.sup.1 is a C.sub.6 -C.sub.22 alkyl group, a group R.sup.4 (OC.sub.n H.sub.2n).sub.x --, where n=2 to 4, x=1 to 6, and R.sup.4 is a C.sub.6 -C.sub.22 alkyl group, or a group R.sup.5 --CONH(CH.sub.2).sub.m, where R.sup.5 is a C.sub.5 -C.sub.21 group and m=2 to 4; R.sup.2 is hydrogen; and R.sup.3 is a C.sub.1 -C.sub.4 alkyl group or a group --(C.sub.n H.sub.2n O).sub.x --H or --(C.sub.n H.sub.2n O).sub.x --PO.sub.3 H.sub.2, where n=2 to 4 and x=1 to 6, or(b) in which R.sup.1 is a C.sub.1 -C.sub.4 alkyl group or a C.sub.2 -C.sub.4 2-hydroxyalkyl group; R.sup.2 is a C.sub.6 -C.sub.22 alkyl group; and R.sup.3 is as defined above.to mixtures thereof with correspondingly substituted phosphate surfactants corresponding to formula (I), in which the --PO.sub.3 H.sub.2 group or groups are replaced by hydrogen; and to neutral and basic salts of the foregoing.

Abstract: An oligomer flame-retarding additive can be defined by the general formula ##STR1## wherein: R is the hydrogen atom, or a linear or branched alkyl radical, containing from 1 to 6 carbon atoms;m takes the value 1, 2 or 3;n takes a value, or an average value, comprised within the range of from 2 to 50.Such an additive is obtained by means of the oligomerization of a hydroxyalkylenephenylphosphinic acid or of a related alkyl ester thereof.According to another form of practical embodiment, the flame-retarding additive is the product of co-oligomerization of a hydroxyalkylenephenylphosphinic acid, or of a related alkyl ester thereof, with a phenylphosphonic acid or a related alkyl ester thereof.Such oligomer additives are used for endowing a linear polyester with self-extinguishing characteristics.

Abstract: A pharmaceutical composition containing as a pharmaceutically active ingredient at least one isomer of inositol triphosphate (IP.sub.3) in an amount sufficient to reduce the negative effect of cadmium or aluminium in the body or inhibit or reduce the formation of free radicals in the body.

Abstract: An inositoltriphosphate (IP.sub.3) selected from the group consisting of D-myo-inositol-1.2.6-triphosphate, D-myo-inositol-1.2.5-triphosphate, L-myo-inositol-1.3.4-triphosphate and myo-inositol-1.2.3-triphosphate, a method for producing the same and a composition comprised of the same.

Abstract: The present invention relates to products of the formula ##STR1## where R.sub.1 is H or alkyl, n is an integer from 0 to 10, and R.sub.2 is chosen from amongst H, unsubstituted or substituted alkyl radicals, a ##STR2## a substituted or unsubstituted phenyl radical, a ##STR3## where X is oxygen or sulfur, or a heterocyclic radical with 5 or 6 members, which may or may not be fused to a benzene ring and R.sub.3 is H or OH.The present invention also relates to a process for the preparation of the products of the formula (I), and to the drugs, having in particular an anti-inflammatory effect, containing a product of the formula (I).

Abstract: A pharmaceutical composition containing as a pharmaceutically active ingredient at least one isomer of inositol triphosphate (IP.sub.3) in an amount sufficient to reduce the negative effect of cadmium or aluminum in the body or inhibit or reduce the formation of free radicals in the body.

Abstract: Reaction products of 5-norbornene-2,3-dicarboxylic anhydride O,O-dialkyldithiophosphate adduct of the formula ##STR1## have been found to be beneficial additives for functional fluids used in the machinery of motorized vehicles. These additives are effective extreme pressure agents and antiwear agents as well as antioxidants for use in such functional fluids as lubricating oils including automatic transmission fluids and hydraulic fluids.

Abstract: Organic esters of chlorine-containing or bromine-containing phosphorus acids and BIS-GMA, as well as organic esters of phosphorus acids having chlorine or bromine bonded directly to phosphorus, the organic radical of said esters containing at least one polymerizable functional group. Also described are dental liner, restorative, composite, and adhesive compositions containing such organic esters, as well as methods for using such compositions to repair or veneer dental tissue.

Abstract: A composition containing acid halide functional materials, which are useful in the preparation of nylon block polymers, selected from the group consisting of: ##STR1## wherein, X is a halogen;b is an integer equal to 2 or more;R.sub.1 is an alkyl, aryl, aralkyl, alkyloxy, halogen, aryloxy, or aralkyloxy group; andZ is a segment of: (1) a polyether, provided said polyether is not solely polyarylene polyether; (2) a polyester containing polyether or polymeric hydrocarbon segments (3) a polysiloxane; or (4) combinations thereof.